Intervention

Axatilimab

ClinicalTrials.gov intervention label

Clinical trials3

Recruiting2

Common conditions6

Lead sponsors shown2

Clinical trials

3 shown

Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast CancerNCT06488378 · 2024-08-13

Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and RadiationNCT05491226 · 2023-11-17

ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and RadiationNCT07015853 · 2026-06-01

NOT_YET_RECRUITING

Common conditions

Breast Cancer3 TNBC - Triple-Negative Breast Cancer2 BRCA1 Mutation1 BRCA2 Mutation1 HER2-negative Breast Cancer1 PALB2-Mutated Breast Carcinoma1

Leading sponsors

Stephen Shiao2 Dana-Farber Cancer Institute1

Trial status mix

RECRUITING2

NOT_YET_RECRUITING1

Phase mix

PHASE22

PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.